Comparing available treatments for pollen-induced allergic rhinitis in children

Area of Science:

• Pediatric Allergy and Immunology
• Respiratory Medicine
• Inflammatory Diseases

Background:

• Pollen-induced allergic rhinitis (PIAR) is a prevalent and increasing condition in children, often co-occurring with asthma.
• Current management follows ARIA guidelines, utilizing allergen avoidance and symptomatic treatments like antihistamines and nasal corticosteroids.
• Emerging therapies include allergen-specific immunotherapy (AIT), anti-IgE antibodies, probiotics, and nutraceuticals.

Purpose of the Study:

• To review and compare established and novel therapeutic strategies for pediatric PIAR.
• To highlight the unique role of AIT as a causal treatment for PIAR.
• To discuss advancements in PIAR management, including combination therapies and new AIT formulations.

Main Methods:

• Literature review of therapeutic strategies for PIAR in children.
• Analysis of current treatment guidelines (ARIA).
• Evaluation of emerging treatments such as AIT, biologics, nutraceuticals, and combination therapies.

Main Results:

• Allergen-specific immunotherapy (AIT) is the sole causal treatment for PIAR.
• New therapeutic approaches involve fixed drug combinations, nutraceuticals, and novel AIT formulations.
• Biologics offer potential benefits for children with PIAR and severe asthma or allergic comorbidities.

Conclusions:

• AIT remains the cornerstone for causal treatment of pediatric PIAR.
• Advancements in AIT formulations and combination therapies offer new avenues for management.
• Integrated treatment approaches, including biologics for severe cases, are expanding therapeutic options.